Progyny Valuation
PGNY Stock | USD 23.25 0.34 1.44% |
At this time, the company appears to be overvalued. Progyny holds a recent Real Value of $21.81 per share. The prevailing price of the company is $23.25. Our model determines the value of Progyny from analyzing the company fundamentals such as Return On Equity of 0.12, operating margin of 0.04 %, and Shares Outstanding of 85.15 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Progyny's price fluctuation is not too volatile at this time. Calculation of the real value of Progyny is based on 3 months time horizon. Increasing Progyny's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Progyny is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Progyny Stock. However, Progyny's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 23.25 | Real 21.81 | Hype 23.28 | Naive 23.53 |
The intrinsic value of Progyny's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Progyny's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Progyny helps investors to forecast how Progyny stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Progyny more accurately as focusing exclusively on Progyny's fundamentals will not take into account other important factors: Progyny Total Value Analysis
Progyny is at this time estimated to have valuation of 1.74 B with market capitalization of 2.01 B, debt of 19.39 M, and cash on hands of 122.39 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Progyny fundamentals before making equity appraisal based on enterprise value of the companyTakeover Price | Market Cap | Debt Obligations | Cash |
1.74 B | 2.01 B | 19.39 M | 122.39 M |
Progyny Investor Information
About 93.0% of the company shares are owned by institutional investors. The book value of Progyny was at this time reported as 4.92. The company had not issued any dividends in recent years. Based on the key measurements obtained from Progyny's financial statements, Progyny is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Progyny Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Progyny has an asset utilization ratio of 143.88 percent. This suggests that the Company is making $1.44 for each dollar of assets. An increasing asset utilization means that Progyny is more efficient with each dollar of assets it utilizes for everyday operations.Progyny Ownership Allocation
The majority of Progyny outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Progyny to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Progyny. Please pay attention to any change in the institutional holdings of Progyny as this could imply that something significant has changed or is about to change at the company. On January 15, 2025, Representative Josh Gottheimer of US Congress acquired under $15k worth of Progyny's common stock.Progyny Profitability Analysis
The company reported the previous year's revenue of 1.09 B. Net Income was 62.04 M with profit before overhead, payroll, taxes, and interest of 246.82 M.About Progyny Valuation
Our relative valuation model uses a comparative analysis of Progyny. We calculate exposure to Progyny's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Progyny's related companies.Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York. Progyny operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 311 people.
Progyny Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Common Stock Shares Outstanding | 100.7 M | |
Quarterly Earnings Growth Y O Y | -0.313 | |
Forward Price Earnings | 14.6199 |
Additional Tools for Progyny Stock Analysis
When running Progyny's price analysis, check to measure Progyny's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Progyny is operating at the current time. Most of Progyny's value examination focuses on studying past and present price action to predict the probability of Progyny's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Progyny's price. Additionally, you may evaluate how the addition of Progyny to your portfolios can decrease your overall portfolio volatility.